Beam Therapeutics logo

Beam TherapeuticsNASDAQ: BEAM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

06 February 2020

Next earnings report:

05 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.77 B
-73%vs. 3y high
79%vs. sector
-vs. 3y high
-vs. sector
-73%vs. 3y high
58%vs. sector
-99%vs. 3y high
60%vs. sector

Price

pre-market | 4 min ago
$21.50-$2.94(-12.03%)

Dividend

No data over the past 3 years
$11.77 M$14.50 M
$11.77 M-$91.05 M

Analysts recommendations

Institutional Ownership

BEAM Latest News

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
zacks.com05 November 2024 Sentiment: -

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago.

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
globenewswire.com05 November 2024 Sentiment: POSITIVE

Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting

Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
zacks.com05 September 2024 Sentiment: NEUTRAL

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
zacks.com06 August 2024 Sentiment: NEUTRAL

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.08 per share a year ago.

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
globenewswire.com06 August 2024 Sentiment: POSITIVE

U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa)

Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
zacks.com26 July 2024 Sentiment: POSITIVE

Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

3 Gene Editing Stocks Shaping the Future of Medicine
investorplace.com22 July 2024 Sentiment: POSITIVE

Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.

Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
zacks.com16 July 2024 Sentiment: NEGATIVE

Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.

Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
zacks.com11 July 2024 Sentiment: POSITIVE

Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.

Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com09 July 2024 Sentiment: POSITIVE

Beam Therapeutics (BEAM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What type of business is Beam Therapeutics?

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

What sector is Beam Therapeutics in?

Beam Therapeutics is in the Healthcare sector

What industry is Beam Therapeutics in?

Beam Therapeutics is in the Biotechnology industry

What country is Beam Therapeutics from?

Beam Therapeutics is headquartered in United States

When did Beam Therapeutics go public?

Beam Therapeutics initial public offering (IPO) was on 06 February 2020

What is Beam Therapeutics website?

https://beamtx.com

Is Beam Therapeutics in the S&P 500?

No, Beam Therapeutics is not included in the S&P 500 index

Is Beam Therapeutics in the NASDAQ 100?

No, Beam Therapeutics is not included in the NASDAQ 100 index

Is Beam Therapeutics in the Dow Jones?

No, Beam Therapeutics is not included in the Dow Jones index

When was Beam Therapeutics the previous earnings report?

No data

When does Beam Therapeutics earnings report?

The next expected earnings date for Beam Therapeutics is 05 November 2024